Caprock Group LLC Invests $304,000 in argenx SE (NASDAQ:ARGX)

Caprock Group LLC acquired a new position in shares of argenx SE (NASDAQ:ARGX - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 494 shares of the company's stock, valued at approximately $304,000.

Other hedge funds have also modified their holdings of the company. Sanctuary Advisors LLC purchased a new position in argenx during the second quarter worth approximately $755,000. GAMMA Investing LLC raised its position in shares of argenx by 47.5% in the 3rd quarter. GAMMA Investing LLC now owns 174 shares of the company's stock worth $94,000 after buying an additional 56 shares during the period. Perpetual Ltd acquired a new position in argenx in the third quarter valued at $76,314,000. Ritholtz Wealth Management purchased a new stake in argenx during the third quarter valued at about $262,000. Finally, Creative Planning grew its position in argenx by 54.1% during the third quarter. Creative Planning now owns 5,437 shares of the company's stock valued at $2,947,000 after acquiring an additional 1,909 shares during the period. 60.32% of the stock is owned by institutional investors and hedge funds.

argenx Trading Down 0.0 %

NASDAQ ARGX traded down $0.19 during trading hours on Monday, reaching $646.45. 197,835 shares of the company traded hands, compared to its average volume of 274,163. The company has a 50 day moving average of $637.69 and a two-hundred day moving average of $578.86. The stock has a market capitalization of $39.28 billion, a PE ratio of -734.60 and a beta of 0.58. argenx SE has a 12 month low of $349.86 and a 12 month high of $678.21.

Analyst Ratings Changes

Several equities analysts have recently weighed in on ARGX shares. Baird R W lowered argenx from a "strong-buy" rating to a "hold" rating in a research note on Friday, November 1st. Guggenheim lifted their price target on shares of argenx from $585.00 to $665.00 and gave the company a "buy" rating in a research report on Friday, November 1st. Deutsche Bank Aktiengesellschaft lowered shares of argenx from a "hold" rating to a "sell" rating in a research report on Friday, January 17th. Truist Financial restated a "buy" rating and set a $700.00 target price (up previously from $660.00) on shares of argenx in a report on Tuesday, January 14th. Finally, JPMorgan Chase & Co. raised their price objective on argenx from $640.00 to $670.00 and gave the company an "overweight" rating in a research report on Monday, November 4th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $658.39.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.